Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of GST-HG131 Tablets

NCT04499443 | Unknown Phase 1

• 1 other identifier: GST-HG131-20-02
• Study Type: interventional
• Target: 124
• Locations: 1 country
• Sites: 1

Brief Summary

To Evaluate the Safety, Tolerability and Pharmacokinetics of GST-HG131 Tablets in Single-center, Randomized, Double-blind, Placebo-controlled Multiple-dose, Single-dose, Multiple-dose Phase Ia Clinical Trials in Healthy Subjects

Conditions

Hepatitis B

Outcome Measures

Primary Outcomes (4)

• Peak Plasma Concentration (Cmax)

  Plasma samples were collected at different points for pharmacokinetic analysis

  Measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 120hours in single-dosing. In the multiple dose group, measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24hours on Day1, more details in protocol.

• Area Under Curve (AUC)

  Plasma samples were collected at different points for pharmacokinetic analysis

  Measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 120hours in single-dosing. In the multiple dose group, measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24hours on Day1, more details in protocol.

• T1/2

  Plasma samples were collected at different points for pharmacokinetic analysis

  Measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 120hours in single-dosing. In the multiple dose group, measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24hours on Day1, more details in protocol.

• Cl/F

  Plasma samples were collected at different points for pharmacokinetic analysis

  Measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 120hours in single-dosing. In the multiple dose group, measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24hours on Day1, more details in protocol.

Secondary Outcomes (2)

• Ae(0~120h)

  Measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 120hours in single-dosing. In the multiple dose group, measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24hours on Day1, more details in protocol.

• Fe(0~120h)

  Measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 120hours in single-dosing. In the multiple dose group, measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24hours on Day1, more details in protocol.

Study Arms (6)

Single-dose experimental group

EXPERIMENTAL

10mg, 30mg, 60mg, 100mg, 150mg, 200mg, 250mg and 300mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo. Each group was administered once, under the fasting condition of Day1, and the tolerance was evaluated on Day2，Day4 and Day6. Subjects in different dose groups were enrolled in turn, and the next set of trials was conducted on the premise that the previous set of tolerability assessments were tolerated. The actual completion of the final dose, depending on the test results.

Drug: GST-HG131 tablets

Single-dose control group

PLACEBO COMPARATOR

10mg, 30mg, 60mg, 100mg, 150mg, 200mg, 250mg and 300mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo.

Drug: Placebo

Multi-dose experimental group

EXPERIMENTAL

According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo. It is necessary to decide the multiple administration method and dosage according to the result of single administration, which is initially determined to be once a day. After the first dose, Day3, Day6, Day8 and Day12 were evaluated for tolerance, and the next group of tests was conducted under the premise that the previous group of Day12 tolerance evaluation was tolerated.

Drug: GST-HG131 tablets

Multi-dose control group

PLACEBO COMPARATOR

According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo.

Drug: Placebo

Food Impact Study Group A

EXPERIMENTAL

Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 \~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 \~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day2, Day4 and Day6 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.

Drug: GST-HG131 tablets

Food Impact Study Group B

EXPERIMENTAL

Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 \~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 \~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day2, Day4 and Day6 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.

Drug: GST-HG131 tablets

Interventions

GST-HG131 tablets DRUG

This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.

Food Impact Study Group A; Food Impact Study Group B; Multi-dose experimental group; Single-dose experimental group

Placebo DRUG

This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.

Multi-dose control group; Single-dose control group

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Sign the informed consent before the trial and fully understand the content, process and possible adverse reactions of the trial;
• Ability to complete research in accordance with test plan requirements;
• Subjects (including partners) are willing to take effective pregnancy avoidance measures within 6 months after screening to the last study drug administration;
• Male and female healthy subjects aged 18 to 55 years (including 18 and 55 years old);
• Male subjects weigh no less than 50 kg, and female subjects weigh no less than 45 kg. Body mass index (BMI) = body weight (kg) / height 2 (m2), body mass index is in the range of 18 \~ 28 kg / m2 (including critical value);
• Physical examination, normal or abnormal vital signs have no clinical significance.

You may not qualify if:

• Those who smoked more than 5 cigarettes per day in the 3 months before the trial;
• Allergies (multiple drugs and food allergies);
• Have a history of drug abuse and / or alcoholism (drink 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine);
• Blood donation or massive blood loss (\> 450 mL) within three months before screening;
• Take any drug that changes the activity of liver enzymes 28 days before screening;
• Took any prescription drugs, over-the-counter drugs, any vitamin products, or herbs within 14 days before screening;
• Those who have taken special diets (including dragon fruit, mango, grapefruit, etc.) or have vigorous exercise or other factors affecting drug absorption, distribution, metabolism, excretion, etc. within 2 weeks before screening;
• Combined with inhibitors or inducers of CYP3A4, such as itraconazole, ketoconazole, etc.;
• Major changes in diet or exercise habits recently;
• Have taken the study drug or participated in the drug clinical trial within three months before taking the study drug;
• Have a history of dysphagia or any gastrointestinal disease that affects drug absorption;
• Have any disease that increases the risk of bleeding, such as hemorrhoids, acute gastritis, or gastric and duodenal ulcers;
• Subjects who cannot tolerate a standard meal (two boiled eggs, a piece of buttered bacon toast, a box of fried potato strips, a cup of full-fat milk) (this strip is only applicable to subjects participating in post-meal trials);
• Abnormal ECG has clinical significance;
• Female subjects were breastfeeding during the screening period or during the trial or were preparing for pregnancy recently or had a positive serum pregnancy result;

Sponsors & Collaborators

• Fujian Cosunter Pharmaceutical Co. Ltd: lead

Study Sites (1)

The first hospital of Jilin University

Changchun, Jilin, 130000, China

RECRUITING

Related Publications (2)

• Hu Y, Sun F, Yuan Q, Du J, Hu L, Gu Z, Zhou Q, Du X, He S, Sun Y, Wang Q, Fan L, Wang L, Qin S, Chen S, Li J, Wu W, Mao J, Zhou Y, Zhou Q, Zhang G, Ding CZ. Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection. Bioorg Med Chem Lett. 2022 Nov 1;75:128977. doi: 10.1016/j.bmcl.2022.128977. Epub 2022 Sep 8.

  PMID: 36089112 DERIVED

• Li X, Liu Y, Yao H, Wang M, Gao L, Lou J, Mao J, Wu W, Zhou Y, Tang Y, Yan W, Hu Y, Ding C, Chen S, Niu J, Ding Y. Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial. Antimicrob Agents Chemother. 2022 May 17;66(5):e0009422. doi: 10.1128/aac.00094-22. Epub 2022 Apr 11.

  PMID: 35404074 DERIVED

MeSH Terms

Conditions

Hepatitis B

Interventions

GST-HG131

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Hepadnaviridae Infections; DNA Virus Infections; Virus Diseases; Hepatitis, Viral, Human; Hepatitis; Liver Diseases; Digestive System Diseases

Study Officials

• Junqi Niu, PHD

  The First Hospital of Jilin University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Yanan Tang, MD

CONTACT

+86 13585734994; annie_tyn@163.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 31, 2020
• First Posted: August 5, 2020
• Study Start: August 18, 2020
• Primary Completion: March 31, 2021
• Study Completion: May 31, 2021
• Last Updated: September 24, 2020

Record last verified: 2020-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)